VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Vistagen Therapeutics Fiscal Year 2025 Second Quarter Corporate Update Conference Call.
Vistagen Therapeutics Inc. (VTGN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 2,000,000 | $6,020,000 | 0.17% | |
| 2. | StemPoint Capital Michelle Ross | 1,846,792 | $4,900,565 | -1% | 1.46% |
| 3. | Commodore Capital Egen Atkinson And Michael Kramarz | 1,575,000 | $4,740,750 | 0.29% | |
| 4. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 1,517,696 | $4,568,265 | 0.23% | |
| 5. | Sphera Global Healthcare Fund Doron Breen And Mori Arkin | 808,550 | $2,433,736 | 0.38% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.15 | 775,756 | Large Shareholder | 1,575,000 | 2023-08-07 | Filing | |
| $0.18 | 100,000 | 100,000 | 2022-08-18 | Filing | ||
| $0.18 | 100,000 | 100,000 | 2022-08-18 | Filing | ||
| $0.17 | 300,000 | 334,629 | 2022-08-17 | Filing | ||
| $0.17 | 600,000 | 626,234 | 2022-08-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.89 | 60,000 | Large Shareholder | 20,637,286 | 2022-07-12 | Filing | |
| $3.13 | 30,000 | 72,786 | 2021-09-07 | Filing | ||
| $0.00 | 4,982,103 | 17,897 | 2011-05-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,676,580 | $13,757,621 | 1.52% | |
| 2. | 1,834,512 | $9,429,391 | 0% | |
| 3. | 556,500 | $2,860,410 | 0% | |
| 4. | 346,683 | $1,781,951 | 0% | |
| 5. | 309,800 | $1,592,372 | 0% |
News See All
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, greetings and welcome to Vistagen Therapeutics Fiscal Year 2025 First Quarter Corporate Update Conference Call.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year-End 2024 Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcript
VistaGen Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.31.
11 Most Promising Psychedelic Stocks According to Hedge Funds
In this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge funds.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript
Operator: Good day, everyone and welcome to today's Vistagen Fiscal Year 2024 Second Quarter Corporate Update Conference Call. [Operator Instructions] Please note this call is being recorded.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year 2024 First Quarter Corporate Update Conference Call.
Hedge Fund and Insider Trading News: Odey Asset Management, Greenlight Capital, Brevan Howard Asset Management, Avoro Capital Advisors, Tidewater Inc (TDW), Vistagen Therapeutics, Inc. (VTGN), and More
Brevan Howard Asset Management has appointed Oualid Lahsini as chief executive officer of its Middle East business. Lahsini, who was previously a partner at Ares Management Corp.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2023 Earnings Call Transcript
Operator: Greetings. Welcome to VistaGen Therapeutics Third Quarter Fiscal Year 2023 Results Conference Call. At this time all participants are in a listen-only mode.
10 Best Biotech Stocks Under $5
The biotech industry has seen strong growth in terms of funding through venture capitalists, joint ventures, and co-developments in the recent past.